Treatment of acute myeloid leukemia (AML) with venetoclax failure
Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax.
1. A method for treating acute myeloid leukemia (AML) in a subject in need thereof, the method comprising administering an effective amount of alvocidib to the subject in the absence of venetoclax, wherein the subject has refractory, resistant, or relapsed AML after one or more prior therapies, at least one of which comprises venetoclax and a hypomethylating agent.
2. The method of claim 1 , wherein the hypomethylating agent is azacitidine, decitabine, or azacitidine and decitabine.
3. The method of claim 1 , wherein the one or more prior therapies comprising venetoclax and a hypomethylating agent is an induction therapy.
4. The method of claim 1 , wherein the alvocidib is a compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the alvocidib is a compound having the structure of Formula (I-b):
or a pharmaceutically acceptable salt thereof.
6. A method for treating acute myeloid leukemia (AML) in a subject in need thereof, the method comprising, in the absence of venetoclax:
(i) administering to the subject an effective amount of alvocidib in a first course of treatment;
(ii) administering to the subject an effective amount of cytarabine in a second course of treatment; and
(iii) administering to the subject an effective amount of alvocidib in a third course of treatment;
wherein the subject has refractory, resistant, or relapsed AML after one or more prior therapies, at least one of which comprises venetoclax and a hypomethylating agent.
7. The method of claim 1 , comprising administering to the subject an effective amount of alvocidib in the absence of an additional chemotherapeutic agent for AML, wherein the subject has refractory, resistant, or relapsed AML after an induction therapy comprising venetoclax and a hypomethylating agent.
8. The method of claim 7 , wherein the alvocidib is a compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein:
from about 15 mg/m 2 to about 40 mg/m 2 of the alvocidib is administered by intravenous bolus on day 1 of a 28-day treatment cycle; and
from about 40 mg/m 2 to about 80 mg/m 2 of the alvocidib is administered by intravenous bolus on days 8 and 15 of the 28-day treatment cycle.
10. The method of claim 7 , comprising administering to the subject, in the absence of an additional chemotherapeutic agent for AML:
from about 15 mg/m 2 to about 40 mg/m 2 of a compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof, by intravenous bolus on day 1 of a 28-day treatment cycle; and
from about 40 mg/m 2 to about 80 mg/m 2 of the compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, by intravenous bolus on days 8 and 15 of the 28-day treatment cycle,
wherein the subject has refractory, resistant, or relapsed AML after an induction therapy comprising venetoclax and azacitidine or venetoclax and decitabine.
11. The method of claim 10 , wherein:
about 25 mg/m 2 of the alvocidib is administered by intravenous bolus on day 1 of a 28-day treatment cycle; and
about 50 mg/m 2 of the alvocidib is administered by intravenous bolus on days 8 and 15 of the 28-day treatment cycle.
12. The method of claim 1 , comprising administering to the subject an effective amount of alvocidib and low-dose cytarabine in the absence of an additional chemotherapeutic agent for AML, wherein the subject has refractory, resistant, or relapsed AML after an induction therapy comprising venetoclax and a hypomethylating agent.
13. The method of claim 12 , wherein the alvocidib is a compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein:
from about 15 mg/m 2 to about 40 mg/m 2 of the alvocidib is administered by intravenous bolus on day 1 of a 28-day treatment cycle; and
from about 40 mg/m 2 to about 80 mg/m 2 of the alvocidib is administered by intravenous bolus on day 15 of the 28-day treatment cycle.
15. The method of claim 14 , wherein:
from about 10 mg/m 2 to about 100 mg/m 2 cytarabine is administered per day by injection on days 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of the 28-day treatment cycle.
16. The method of claim 12 , comprising administering to the subject, in the absence of an additional chemotherapeutic agent for AML:
from about 15 mg/m 2 to about 40 mg/m 2 of a compound having the structure of Formula (I):
or a pharmaceutically acceptable salt thereof, by intravenous bolus on day 1 of a 28-day treatment cycle;
from about 10 mg/m 2 to about 100 mg/m 2 cytarabine, per day by injection on days 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of the 28-day treatment cycle; and
from about 40 mg/m 2 to about 80 mg/m 2 of the compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, by intravenous bolus on days 8 and 15 of the 28-day treatment cycle,
wherein the subject has refractory, resistant, or relapsed AML after an induction therapy comprising venetoclax and azacitidine or venetoclax and decitabine.
17. The method of claim 16 , wherein:
about 25 mg/m 2 of the alvocidib is administered by intravenous bolus on day 1 of a 28-day treatment cycle; and
about 50 mg/m 2 of the alvocidib is administered by intravenous bolus on day 15 of the 28-day treatment cycle.
18. The method of claim 16 , wherein:
about 20 mg/m 2 cytarabine is administered per day by injection on days 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 of the 28-day treatment cycle.
19. The method of claim 1 , wherein the subject is a human.
20. A method for inhibiting development of tumor lysis syndrome (TLS) in a subject; reducing the severity of TLS in a subject decreasing mortality from TLS in subjects; reducing the incidence of TLS in subjects; preventing TLS in a subject; or treating AML in a subject without high risk for developing TLS, the method comprising administering alvocidib to the subject at a first dose of from about 15 mg/m 2 to about 40 mg/m 2 in the absence of venetoclax, wherein the subject has refractory, resistant, or relapsed AML after one or more prior therapies, at least one of which comprises venetoclax.